NUCANA PLC

• ⚠

  Material uncertainty over going concern

  Because of these funding needs and related risks, and the current cash balance on hand, there is material uncertainty related to our ability to raise sufficient additional capital within the going concern period, prior to our cash balances being exhausted, which is forecast to occur in the going concern assessment period.

1. NUCANA PLC 2017-08-29 → present
2. NUCANA LIMITED 2017-08-29 → 2017-08-29
3. NUCANA BIOMED LIMITED 2008-04-28 → 2017-08-29
4. BIOMED (UK) LIMITED 1997-01-28 → 2008-04-28

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“Because of these funding needs and related risks, and the current cash balance on hand, there is material uncertainty related to our ability to raise sufficient additional capital within the going concern period, prior to our cash balances being exhausted, which is forecast to occur in the going concern assessment period.”

Group structure

1. NUCANA PLC · parent
   1. NuCana, Inc. 100% · U.S. · Development and administrative support
   2. NuCana BioMed Trustee Company Limited 100% · U.K. · Dormant
   3. NuCana BioMed Employee Benefit Trust 100% · U.K. · Employee benefit trust
   4. NuCana Limited 100% · Ireland · Development and administrative support

Significant events

• “During January 2025, the Group sold and issued 394,303 ADSs, representing 9,857,575 ordinary shares, under the ATM program, raising gross proceeds of £0.5 million.”
• “On 23 April 2025, the Group subdivided and redesignated the issued share capital of 151,923,897 ordinary shares of £0.04 each into 151,923,897 ordinary shares and 15,040,465,803 deferred shares, in each case, of £0.0004 each.”
• “On 7 May 2025, under a registered direct offering, the Group sold and issued 2,452,935 ADSs, representing 61,323,375 ordinary shares, and Pre-Funded Warrants to purchase up to 8,393,050 ADSs, representing 209,826,250 ordinary shares in lieu of ADSs, which were subsequently exercised in full, and accompanying Series A Warrants and Series B Warrants. The offering raised gross proceeds of £5.3 million.”
• “Subsequent to 7 May 2025, the Series B Warrants have been exercised in full and the Group has issued 356,412,705 ADSs, representing 8,910,317,625 ordinary shares, raising gross proceeds of £3.5 million.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

20

last 12 months

Capital events

16

last 24 months

Officers appointed

0

last 12 months

Officers resigned

1

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -60.8%

  £17,225,000 → £6,749,000

• Net assets

  -60%

  £14,887,000 → £5,954,000

• Employees

  -10.3%

  29 → 26

• Operating profit

  +30.4%

  -£32,784,000 → -£22,809,000

• Profit before tax

  +29.9%

  -£32,030,000 → -£22,451,000

• Wages

  -23.1%

  £6,030,000 → £4,638,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers